ZA201505602B - Composition comprising an encapsulated antagomir - Google Patents

Composition comprising an encapsulated antagomir

Info

Publication number
ZA201505602B
ZA201505602B ZA2015/05602A ZA201505602A ZA201505602B ZA 201505602 B ZA201505602 B ZA 201505602B ZA 2015/05602 A ZA2015/05602 A ZA 2015/05602A ZA 201505602 A ZA201505602 A ZA 201505602A ZA 201505602 B ZA201505602 B ZA 201505602B
Authority
ZA
South Africa
Prior art keywords
composition
encapsulated antagomir
antagomir
encapsulated
Prior art date
Application number
ZA2015/05602A
Other languages
English (en)
Inventor
David Garcia-Dorado Garcia Antonio
Barba Vert Ignasi
Rodriguez Sinovas Antonio
Bellera Gotarda Neus
Perez Amadeo
Ferret Eulalia
Asin Miguel-Angel
Original Assignee
Fundacio Hospital Univ Vall D'hebron - Institut De Recerca
Pierre Fabre Medicament S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Hospital Univ Vall D'hebron - Institut De Recerca, Pierre Fabre Medicament S A S filed Critical Fundacio Hospital Univ Vall D'hebron - Institut De Recerca
Publication of ZA201505602B publication Critical patent/ZA201505602B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2015/05602A 2013-01-24 2015-08-04 Composition comprising an encapsulated antagomir ZA201505602B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
ZA201505602B true ZA201505602B (en) 2017-05-31

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/05602A ZA201505602B (en) 2013-01-24 2015-08-04 Composition comprising an encapsulated antagomir

Country Status (16)

Country Link
US (1) US20150352055A1 (enExample)
EP (2) EP2759595B1 (enExample)
JP (1) JP2016506923A (enExample)
KR (1) KR20160018451A (enExample)
CN (1) CN105229151A (enExample)
AU (1) AU2014208419A1 (enExample)
BR (1) BR112015017650A2 (enExample)
CA (1) CA2898958A1 (enExample)
ES (2) ES2606636T3 (enExample)
HK (1) HK1219753A1 (enExample)
HU (1) HUE032125T2 (enExample)
MX (1) MX2015009323A (enExample)
PL (1) PL2759595T3 (enExample)
RU (1) RU2668794C2 (enExample)
WO (1) WO2014115103A1 (enExample)
ZA (1) ZA201505602B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
EP3939575B1 (en) * 2019-03-14 2026-07-01 M. Technique Co., Ltd. PLGA MICROPARTICLES, DELAYED-RELEASE FORMULATION OF THESE AND THEIR MANUFACTURE PROCESS
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P(Asp-AP)-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR20120047214A (ko) * 2009-05-20 2012-05-11 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근경색 후 리모델링 및 심부전에 관련된 마이크로―rna의 확인

Also Published As

Publication number Publication date
KR20160018451A (ko) 2016-02-17
US20150352055A1 (en) 2015-12-10
PL2759595T3 (pl) 2017-09-29
EP2759595A1 (en) 2014-07-30
CA2898958A1 (en) 2014-07-31
JP2016506923A (ja) 2016-03-07
ES2606636T3 (es) 2017-03-24
WO2014115103A1 (en) 2014-07-31
HUE032125T2 (en) 2017-08-28
AU2014208419A1 (en) 2015-08-13
EP2948551A1 (en) 2015-12-02
CN105229151A (zh) 2016-01-06
RU2015134770A (ru) 2017-03-03
BR112015017650A2 (pt) 2017-11-21
ES2688160T3 (es) 2018-10-31
EP2759595B1 (en) 2016-09-14
RU2668794C2 (ru) 2018-10-02
HK1219753A1 (zh) 2017-04-13
EP2948551B1 (en) 2018-05-02
MX2015009323A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
PL3065569T3 (pl) Kompozycja
GB201304662D0 (en) Compositions
HUE044039T2 (hu) Biokatalitikus készítmény
GB201608461D0 (en) Compositions
PL2759595T3 (pl) Kompozycja zawierająca kapsułkowany antagomir
GB201319540D0 (en) Composition
GB201318489D0 (en) Composition
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201320919D0 (en) Composition
GB201320303D0 (en) Composition
GB201317388D0 (en) Composition
SG10201801521QA (en) Anti-obesity composition
GB201319538D0 (en) Composition
GB201306984D0 (en) Composition
GB201322772D0 (en) Composition
GB201317196D0 (en) Composition
IL225985A0 (en) Preparation@cosmetic@mushkollal
GB201307622D0 (en) Composition
PL2767164T3 (pl) Nowe kompozycje
GB201320962D0 (en) Compositions
GB201316082D0 (en) Chitosan composition
SG11201602134QA (en) Encapsulation
GB201420672D0 (en) Composition
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition